IP Library Granted Patent US 8,377,440
Granted Patent B2
US 8,377,440 · App. 12/516,987 · Granted Feb 19, 2013

Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases

Inventors: Rodger P. McEver (Oklahoma City, OK); Richard Alvarez (Edmond, OK); Ziad Kawar (Oklahoma City, OK)
Assignees: Selexys Pharmaceuticals Corporation; Oklahoma Medical Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,440
App. No.
12/516,987
Granted
Feb 19, 2013
Kind
B2
Abstract

The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.

Claims (7)

1. A humanized antibody, or binding fragment thereof, comprising an immunoglobulin light chain variable region comprising SEQ ID NO:36, and an immunoglobulin heavy chain variable region comprising SEQ ID NO:40, and wherein the humanized antibody has binding specificity for P-selectin.

2. The humanized antibody of claim 1 , wherein said antibody binds P-selectin with a dissociation constant less than 10 −7 M.

3. The humanized antibody of claim 1 , wherein said antibody binds P-selectin with a dissociation constant between 10 −7 M and 10 −13 M.

4. The humanized antibody of claim 1 , wherein said humanized antibody is recombinant.

5. The humanized antibody of claim 1 , wherein said antibody is an immunoglobulin G.

6. A pharmaceutical composition comprising the antibody of claim 1 admixed with a pharmaceutically acceptable excipient.

7. A kit comprising the pharmaceutical composition of claim 6 and instructions.

Assignments (5)
CHANGE OF NAME Recorded Jan 26, 2023
From: SELEXYS PHARMACEUTICALS CORPORATION
To: REPRIXYS PHARMACEUTICALS CORPORATION
Reel/Frame 062514/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2019
From: REPRIXYS PHARMACEUTICALS CORPORATION
To: NOVARTIS AG
Reel/Frame 051083/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2012
From: ALVAREZ, RICHARD; KAWAR, ZIAD S.
To: SELEXYS PHARMACEUTICALS CORPORATION
Reel/Frame 027542/0405 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2012
From: MCEVER, RODGER P.
To: OKLAHOMA MEDICAL RESEARCH FOUNDATION
Reel/Frame 027542/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2010
From: MCEVER, RODGER P.; ALVAREZ, RICHARD; KAWAR, ZIAD
To: SELEXYS PHARMACEUTICALS CORPORATION
Reel/Frame 024012/0958 →
Continuity (2)
Provisional Application 60872170 · Dec 1, 2006
Related Publication 20110243926A1 · Oct 6, 2011